Faron Pharmaceuticals Oy (LON:FARN) fell 3.3% during mid-day trading on Friday . The stock traded as low as GBX 103 ($1.35) and last traded at GBX 103 ($1.35), 20,450 shares were traded during trading. An increase of 41% from the average session volume of 14,501 shares. The stock had previously closed at GBX 106.50 ($1.39).
The company has a debt-to-equity ratio of 577.78, a quick ratio of 0.87 and a current ratio of 1.19. The company has a 50-day simple moving average of GBX 110.77 and a 200-day simple moving average of GBX 92.71. The company has a market cap of $41.91 million and a price-to-earnings ratio of -0.97.
About Faron Pharmaceuticals Oy (LON:FARN)
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute organ traumas, vascular damage, and cancer immunotherapy. The company's lead product candidate is Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS).
Featured Article: Trading on Margin
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.